Register for our free email digests:
Massachusetts Institute of Technology
Latest From Massachusetts Institute of Technology
BridgeBio's hub-and-spoke model is similar to the Roivant and Fortress strategies, but with a focus on drug candidates for genetic diseases in need of a bridge to future funding.
Merck adds to its immuno-oncology R&D heft with purchase of Rigontec, while Allergan will collaborate with Lyndra to produce once-weekly drugs for Alzheimer’s disease.
Untapped market opportunities for treating and possibly curing underserved diseases have spurred an active deal-making environment in regenerative medicine, according to a new report from Datamonitor Healthcare.
Antibiotic incentives, vaccine strategies, drug pricing, patent updates and more hot topics from the Biotechnology Innovation Organization's recent annual conference.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.